Your SlideShare is downloading. ×
MeTA introduction
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

MeTA introduction

627
views

Published on

Presentation by Wilbert Bannenberg, Technical Director, International MeTA Secretariat on MeTA during the 69th FIP Congress, Istanbul, September 2009.

Presentation by Wilbert Bannenberg, Technical Director, International MeTA Secretariat on MeTA during the 69th FIP Congress, Istanbul, September 2009.


0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
627
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • Title of presentation 21/01/10 MeTA
  • Title of presentation 21/01/10 MeTA
  • Title of presentation 21/01/10 MeTA
  • Title of presentation 21/01/10 MeTA
  • Title of presentation 21/01/10 MeTA
  • Title of presentation 21/01/10 MeTA
  • Transcript

    • 1. Wilbert Bannenberg Technical Director International MeTA Secretariat 5 September 2009, FIP 2009 Congress, Istanbul Medicines Transparency Alliance (MeTA) MeTA FIP 05/09/2009
    • 2. What is MeTA?
      • An international alliance between:
        • DFID, World Bank, WHO, private sector, NGOs, professional organisations.
      • Alliances in 7 pilot countries to focus on what can be done to increase access to medicines.
        • - Government, CSOs and Private Sector
      • An International Secretariat to support country work, and, upon request, technical assistance.
      05/09/2009 MeTA FIP
    • 3. What does MeTA want to achieve?
      • MeTA goal: to increase access to essential medicines, especially for the poor in developing countries
      • Essential medicines still valid concept
      • But, after 30 years, 2 billion people are still not having access
      • What can we do better?
      05/09/2009 MeTA FIP
    • 4. Added value of MeTA?
      • Country led, bottom-up approach
      • Multi-stakeholder collaboration
      • Improved transparency and disclosure of all players should lead to better information & greater accountability in the supply chain
      05/09/2009 MeTA FIP
    • 5. The scope of MeTA
      • Currently 7 countries are piloting MeTA (until September 2010)
      • Global collaboration with private sector, NGOs, donors and professional organisations
      05/09/2009 MeTA FIP
    • 6. Transparency?
      • Improving information access, scrutiny and use, in order to support the development of viable, efficient medicines markets and supply systems that benefit all developing country consumers
      • Transparency = not only disclosure of the price, quality of medicines; but also:
        • Jointly use the information to identify barriers, and
        • Jointly seek better solutions!
      MeTA FIP 05/09/2009
    • 7. Drug Supply – Transparent? Source: SSDS Inc for the World Bank
    • 8. Transparent? 05/09/2009 MeTA FIP Source: TI Global corruption report 2006
    • 9. Areas where transparency can help… 05/09/2009 MeTA FIP Source: TI Global corruption report 2006
    • 10. Transparency in pharmacy practice?
      • Transparency should be an integral part of Good Pharmacy Practice!
      • Pharmacists can help in both public and private sector
      • Welcome in MeTA!
      05/09/2009 MeTA FIP
    • 11. Contact?
      • Wilbert Bannenberg
      • [email_address]
      • Mobile: +31-6-20873123
      • MeTA website: www.MedicinesTransparency.org
      MeTA FIP 05/09/2009